Day 2 - Wednesday, November 19, 2025 - ET (Eastern Time, GMT-05:00)
- Chris Dowd - Senior Vice President, ConnectiveRx
What return can you expect from an investment in patient access and affordability programs if eligible patients aren’t aware of them? During this session, explore practical steps to increasing your brand’s “Activation Quotient” starting today, extending your programs’ reach, increasing enrollment and utilization, and ultimately improving patient outcomes.
Understand the necessity of proactive activation for patient affordability programs to effectively increase patient participation
Leverage external partners to more efficiently reach, identify, and screen eligible patients—at scale
Measure and demonstrate successful integration of medication affordability programs within pharma + partner ecosystems
Overcome common barriers to activation, including lack of data standardization, low patient engagement, and inconsistent technology integration
- Divya Iyer - Senior Vice President, Go-to-Market Strategy, GoodRx
Industry experts will break down the most critical IRA developments, explore how manufacturers are adapting and discuss what’s next as additional policy changes take effect.
Receive an update on how the IRA has reshaped market access and patient services so far
Check in on the progress of Medicare Part D, including patient adoption rates and how the new structure affects copay programs, patient assistance and manufacturer cost exposure
Benchmark with industry peers to hear how other manufacturers are restructuring their patient support programs in response to IRA
Learn how IRA provisions will continue to evolve through 2026 and beyond to inform long-term strategic adjustments
- Marc Appel - Founder and Entrepreneur in Residence, Orange Grove Bio and Yale Ventures
- Joan Rizal - Senior Counsel, Halozyme
As policy shifts and payer tactics reshape the access landscape, manufacturers must evolve their copay strategies. This session offers a practical guide to designing future-ready copay programs—scalable, compliant and aligned with GTN realities. Learn how to integrate AI responsibly, navigate accumulators and build operational models that adapt to change while keeping patients at the center.
- Tate Williams - Senior Director, Affordability and Insights, CoverMyMeds
The accumulator, maximizer, and alternative funding program landscape is rapidly evolving, creating new hurdles for manufacturers aiming to preserve patient affordability.
Gain insights into the future of accumulators and maximizers and whether regulatory changes could shift payer and PBM cost-containment strategies
Navigate the growing patchwork of state laws impacting copay programs and assess risk mitigation strategies for long-term sustainability
- Rachel Klein - Deputy Executive Director, The AIDs Institute
- Carl Schmid - Executive Director, HIV + Hepatitis Policy Institute
In this closed-door summit, benchmark with industry peers on best practices for risk mitigation, payer negotiations and copay program design as cost sharing programs continue to disrupt the marketplace.
**Attendance for this session is limited and RSVP is required. To secure a spot, please email callie.mertel@informa.com. Attendance is at the discretion of Informa Connect.
- Richard Fahrer - Director, Oncology Patient Solutions & Alliances, Pfizer
- Meredith McDonald - Director, Patient Access, Exelixis, Inc.
Gain key insights on enforcement trends and upcoming areas of focus for 2025 and beyond, specifically looking at guidance on field-based roles, prior authorization and carveout watch-outs.
- David Blank - Partner, Arnall Golden Gregory LLP, Former Senior Counsel, HHS/OIG
- Matthew E. K. Howatt - Former Assistant United States Attorney, Eastern District of Pennsylvania; Current Senior Director, Head of Legal Affairs, Sun Pharmaceutical Industries, Inc
In an era of increasing payer restrictions, evolving reimbursement models and shifting patient affordability challenges, how manufacturers communicate about copay and patient support programs is more critical than ever. This session explores how manufacturers can strike the right balance between proactive and reactive communication to enhance stakeholder education, patient engagement and program success.
- Connie Frangakis - Associate Director, Operational Excellence, Patient Services, Kyowa Kirin, Inc.
Learn strategies on how to evaluate the utilization and effectiveness of FRMs
Uncover opportunities to increase customer satisfaction
Understand risk areas, such as sourcing and sharing data, and how to mitigate compliantly
Identify key challenges, such as cost sharing programs, and how to train FRMs accordingly
- Jen Murdock - Associate Director, Field Access & Reimbursement, Johnson and Johnson Innovative Medicine
This session explores the complexities of operationalizing specialty pharmacy in Rare Disease, with a focus on balancing patient access with market considerations for physician-administered therapies. Address the challenges manufacturers face in navigating payer policies and managing medical versus pharmacy benefit access.
Run through the advantages and challenges associated with specialty pharmacy in rare disease, including strategies for effective operationalization
Navigate the patient journey through medical billing, copay programs and their impact on treatment access
Balance buy-and-bill vs. specialty pharmacy channels for physician-administered therapies in rare diseases
Uncover strategies for manufacturers to collaborate with specialty pharmacies to navigate payer policies and optimize patient support programs
- Sheila Bhattacharya - Vice President, Market Access and Strategic Accounts, Azurity Pharmaceuticals
- Usha Roy - Senior Director - Patient Support and Reimbursement, MASA, Azurity Pharmaceuticals